Table 1.
Patient characteristics at baseline, n = 303
| Characteristic | N (%) or Median (IQR) | |
|---|---|---|
| Age (years) | 56 | (47–65) |
| Weight (kg) | 73.5 | (65.3–84.0) |
| BMI (kg m−2) | 26 | (22.8–29.7) |
| Tamoxifen (nmol/L) | 308 | (248.0–385.5) |
| Endoxifen (nmol/L) | 26.2 | (17.0–35.3) |
| CYP2D6, phenotype | ||
| PM | 25 | (8.2) |
| IM | 99 | (32.7) |
| NM | 177 | (58.4) |
| Missing data | 2 | (0.7) |
| CYP2D6 inhibitor | ||
| Weak inhibitor | 4 | (1.3) |
| Strong inhibitor | 1 | (0.3) |
| No inhibitor | 298 | (98.4) |
| CYP3A4*22 genotype | ||
| CC | 269 | (88.8) |
| CT/TT | 28 | (9.2) |
| Missing data | 6 | (2) |
| CYP3A4/5 inhibitors | ||
| Weak inhibitor | 12 | (4) |
| No inhibitor | 291 | (96) |
| Morisky Medication Adherence Scale | ||
| High adherence (n/N) | 132 | (91) |
| Medium adherence (n/N) | 7 | (5) |
| Low adherence (n/N) | 6 | (4) |
| Missing data | 158 | (52.1) |
BMI Body Mass Index, CYP2D6 strong inhibitor: quinidine; CYP2D6 weak inhibitors: escitalopram, sertraline, and citalopram; CYP3A weak inhibitors: pantoprazole, prednisone and omeprazole. PM poor metabolizer; IM intermediate metabolizer; NM normal metabolizer